A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05208762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Study identification
- NCT ID
- NCT05208762
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 714 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2022
- Primary completion
- Jan 4, 2028
- Completion
- Jan 3, 2029
- Last update posted
- Jul 21, 2026
2022 – 2029
United States locations
- U.S. sites
- 25
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| University of Alabama at Birmingham, IDS Pharmacy | Birmingham | Alabama | 35249 | Recruiting |
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | Recruiting |
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | California | 92612 | Recruiting |
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868 | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | Recruiting |
| University of California, Davis Medical Center | Sacramento | California | 95817 | Recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Karmanos Cancer Institute | Farmington Hills | Michigan | 48334 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| University of Texas Southwestern Medical Center - Simmons Cancer Center | Dallas | Texas | 75235 | Recruiting |
| UT Southwestern Medical Center - Redbird | Dallas | Texas | 75237 | Recruiting |
| Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital | Dallas | Texas | 75390 | Recruiting |
| University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital | Dallas | Texas | 75390 | Recruiting |
| University Of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| UT Southwestern - Simmons Cancer Center - Fort Worth | Fort Worth | Texas | 76104 | Recruiting |
| The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services | Houston | Texas | 77030 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| UT Southwestern - Simmons Cancer Center - Richardson/Plano | Richardson | Texas | 75080 | Recruiting |
| NEXT Virginia, LLC | San Antonio | Texas | 78229 | Recruiting |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05208762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05208762 live on ClinicalTrials.gov.